CD4 Cell Response to Antiretroviral Therapy in Children with Vertically Acquired HIV Infection: Is It Associated with Age at Initiation?

April 2006
Journal of Infectious Diseases;4/1/2006, Vol. 193 Issue 7, p954
Academic Journal
Background. Considerable uncertainty remains as to whether early initiation of antiretroviral therapy (ART) in children with vertically acquired human immunodeficiency virus (HIV) infection increases the benefit in terms of immunological response. Methods. The association between immunological outcome and early initiation of and/or more-potent ART was investigated, using age-standardized z scores for CD4 cell counts (hereafter, ‘CD4 z scores’), in 131 HIV-infected children enrolled in the European Collaborative Study, a birth cohort study. Results. Median age at initiation of the most-potent ART was 4 years (range, 0.1–15.5 years). Initiation of treatment after 5 months of age resulted in nonsignificantly lower CD4 z scores 6 months after initiation. Time to a 20% increase in CD4 z score was associated with age at initiation of the most-potent ART (adjusted hazard ratios [AHRs], 0.37 [P<.01] and 0.43 [P = .05] for 5 months-5 years of age and 15 years of age, respectively, compared with <5 months of age), ethnicity (AHR, 0.48 [P = .01], for black vs. white), and highly active ART (HAART) with or without prior ART (AHRs, 3.16 [P<.01] and 3.95 [P<.001], vs. mono or dual ART, respectively). The risk of subsequent deterioration of CD4 z score was similar for children who initiated ART in different age groups (χ² = 0.824; P = .82). Conclusions. We confirm the effectiveness of HAART with respect to the recovery of CD4 cell count and suggest a benefit of initiating ART before the age of 5 months. Age at initiation of the most-potent ART was not associated with the likelihood of sustaining the recovery of CD4 cell count.


Related Articles

  • Effects of Human Leukocyte Antigen Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of Highly Active Antiretroviral Therapy. Brumme, Zabrina L.; Brumme, Chanson J.; Chui, Celia; Mo, Theresa; Wynhoven, Brian; Woods, Conan K.; Henrick, Bethany M.; Hogg, Robert S.; Montaner, Julio S. G.; Harrigan, P. Richard // Journal of Infectious Diseases;6/1/2007, Vol. 195 Issue 11, p1694 

    Background. Human leukocyte antigen (HLA) class I variation influences the progression of untreated human immunodeficiency virus (HIV) disease; however, it is not known whether HLA class I variation may influence clinical outcomes after initiation of highly active antiretroviral therapy (HAART)....

  • A mutant retroviral receptor restricts virus superinfection interference and productive infection. Meihong Liu; Eiden, Maribeth V. // Retrovirology;2012, Vol. 9 Issue 1, p51 

    Background: Both cell-free and cell-associated infection routes are important for retroviral dissemination. Regardless of the mechanism, the driving force of retroviral entry is the interaction between the viral envelope and its receptor. To date it remains unclear how decreased affinity of...

  • Viral Infections. Adair, Ann // PN;Sep2005, Vol. 59 Issue 9, p24 

    Presents the fourth and final part in a series of articles about antibiotics and other medications that can be used to viral infections. Response of the immune system when a viral infection is detected; Capability of the immune system to remember specific pathogenic viruses and to effectively...

  • 5-(1-Substituted) Alkyl Pyrimidine Nucleosides as Antiviral (herpes) Agents. Kumar, Rakesh // Current Medicinal Chemistry;Oct2004, Vol. 11 Issue 20, p2749 

    The treatment of viral diseases remains one of the major challenges to modem medicine. During the past two decades there has been increased recognition of the consequences of serious viral illnesses that are not controlled by vaccination. These illnesses include human immunodeficiency virus,...

  • Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. RAZONABLE, RAYMUND R. // Mayo Clinic Proceedings;Oct2011, Vol. 86 Issue 10, p1009 

    Most viral diseases, with the exception of those caused by human immunodeficiency virus, are seifilmited ilinesses that do not require specific antivirai therapy. The currentiy avaiiabie antivirai drugs target 3 main groups of viruses: herpes, hepatitis, and influenza viruses. With the exception...

  • Spermicides, Microbicides and Antiviral Agents: Recent Advances in the Development of Novel Multi-Functional Compounds. Baptista, Marta; Ramalho-Santos, Jo�o // Mini Reviews in Medicinal Chemistry;Nov2009, Vol. 9 Issue 13, p1556 

    Non-ionic surfactants have been proposed as dual action anti-viral and spermicidal agents to tackle viral infec- tions, namely HIV. Given very promising in vitro results, nonoxynol-9 has been widely used. However, toxic effects were reported, paradoxically increasing the incidence of...

  • Strategies for the Scale-Up of Antiretroviral Therapy in South Africa through Health System Optimization. Barker, Pierre M.; McCannon, C. Joseph; Mehta, Nupur; Green, Cathryn; Youngleson, Michele S.; Yarrow, Justin; Bennett, Brandon; Berwick, Donald M. // Journal of Infectious Diseases;12/2/2007, Vol. 196 Issue S3, pS457 

    In the face of the massive burden created by human immunodeficiency virus/acquired immunodeficiency syndrome and other infectious diseases, developing nations must find ways to rapidly begin treatment for infected persons. Although infusions of personnel, supplies, and diagnostics would make a...

  • Prevention of Human Immunodeficiency Virus Type 1 Transmission by Pharmaceuticals Targeted to Host Proteins Required for Virus Infection? Consideration of Farnesyl Thiosalicylic Acid, a Ras Inhibitor. Neurath, A. Robert; Lackman-Smit, Carol // Journal of Antivirals & Antiretrovirals;2009, Vol. 1 Issue 1, p72 

    Recent success in defining the human immunodeficiency virus type 1 (HIV-1) - host cell protein interaction network has provided an opportunity for development of novel antiviral therapeutics targeted to host proteins required for virus infection. This expanded earlier successful development of...

  • Temporomandibular Joint Disorders During HIV Infection: A Case Report. Fiorentino, Paolo M.; Piancino, Maria G.; Debernardi, Cesare; Attard, Nikolai // Journal of Orofacial Pain;Spring2009, Vol. 23 Issue 2, p174 

    Temporomandibular disorders (TMD) is a term reflecting chronic, painful, craniofacial conditions usually of unclear etiology with impaired jaw function. Human immunodeficiency virus (HIV)- infected patients often report chronic pain and pathologies targeting body joints during retroviral...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics